5 Endocrinology Headlines You Missed in November 2025

While largely a quiet month for endocrinology, November 2025 was not without its important updates. There were no significant approvals from the US Food and Drug Administration, but glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have continued their advances into other condition centers such as nephrology and cardiology. Additionally, Novo Nordisk has had a rollercoaster month, between the failure of semaglutide to significantly reduce Alzheimer’s progression and amycretin’s superior weight loss outcomes in patients with type 2 diabetes (T2D) compared to placebo.

The editorial team at HCPLive has collected 5 of the most impactful headlines to come out of endocrinology in the last month. Check them out below to catch up on any news you might have missed.

Trial Results

Novo Nordisk’s Amycretin Demonstrates Superior Weight Loss Versus Placebo

On November 25, 2025, Novo Nordisk announced the success of their phase 2 clinical trial of amycretin, an investigative drug administered once-weekly subcutaneously or once-daily orally, in triggering weight loss and HbA1c reductions in patients with T2D. Based on these positive results, the company has also announced its intention to begin a phase 3 program at some point in 2026.

Investigative Amylin Agonist Eloralintide Proves Superiority to Placebo in Weight Management

Eloralintide displayed superior mean weight reductions versus placebo among adult patients with obesity and ≥1 weight-related comorbidity. The once-weekly selective amylin receptor agonist has the capacity to decrease calorie intake, which clinicians attribute to potential effects on satiety. Eloralintide is also under investigation both alone and with tirzepatide for weight management in adults with overweight or obesity and T2D.

Semaglutide Provides Cardiorenal Benefits in CKD With or Without Diabetes

A recent meta-analysis has highlighted a connection between semaglutide and favorable safety profiles in patients with chronic kidney disease, regardless of the presence of diabetes. During 5 randomized clinical trials, semaglutide was shown to lower the risk of major adverse cardiovascular events, kidney-related complications, and cardiovascular mortality. Investigators used these data to highlight the need for enhanced generalizability of GLP-1 data in nephrological diseases.

Other Updates

Diabetes Dialogue: Updates on Dexcom G7 and Semaglutide Pricing

In this episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discussed Dexcom’s announcement of the 15-day G7 sensor, which launched on December 1 through durable medical equipment channels and is planned to launch in pharmacies in January of 2026. The new sensor will integrate with the existing app platform and maintain the same accuracy profile, with a 15.5-day life via a built-in 12-hour grace period. Additionally, Isaacs and Bellini covered the significant price changes to Ozempic and Wegovy, with both drugs across all doses dropping to $199 for the first 2 months and $349 thereafter.

Diabetes Dialogue: Semaglutide Falls Short in Alzheimer Disease, Tirzepatide Shows Promise in T1D

In this episode, Isaacs and Bellini discuss Novo Nordisk’s negative results after the Evoke and Evoke+ phase 3 trials, both of which failed to show a reduction in disease progression speed in Alzheimer’s disease with oral semaglutide 14 mg. Although both trials saw improvements in related biomarkers, their failure to slow Alzheimer’s progression resulted in Novo Nordisk discontinuing a planned 1-year extension. However, these disappointing results are offset up the success of the TIRTLE phase 2 trial, which showed tirzepatide’s benefit in weight loss in adult patients with type 1 diabetes (T1D). Tirzepatide also improved glycemic control, reduced HbA1c, and decreased total daily insulin dose relative to placebo, all without significant adverse events.